Sentinel Therapeutics, Inc

Glycosensors & Diagnostics, LLC, based in Athens, GA, specializes in providing validated glycoscience products and services designed to enhance scientific research in glycan detection, processing, and profiling. Their offerings include a range of enzymes, multiplex bead-based analysis kits, and optimized buffers and accessories to ensure reliable experimental results. Committed to empowering scientists, Glycosensors & Diagnostics, LLC aims to make advanced glycoscience tools accessible to researchers across various fields. The company prides itself on its innovative technology and dedication to supporting the scientific community in their pursuit of precise and effective glycan analysis. Generated from the website

Reprotox Biotech LLC is a biotechnology company based in Albuquerque, NM, specializing in the development of advanced in vitro models for reproductive toxicity testing. Their innovative platform includes 3D culture models and machine learning-based high-content image analysis, allowing for the assessment of the efficacy and safety of drugs and chemicals. With a focus on the 3Rs concept of replacement, reduction, and refinement of animals used in science, Reprotox aims to revolutionize preclinical research and contribute to the development of safe and effective pharmaceuticals. Reprotox Biotech LLC supports the discovery efforts of its partners by providing tools, solutions, and services for in vitro reproductive toxicological studies. Their team of highly skilled scientists is dedicated to developing novel in vitro models that have the potential to replace traditional animal models, thereby transforming the future of preclinical research. With a commitment to advancing the field of reproductive toxicology, Reprotox is at the forefront of cutting-edge technology and aims to contribute to the goal of reducing and eventually replacing animal testing.Generated from the website

Pneumotactix, LLC is a biotech company based in Atlanta, Georgia, focused on enhancing the immune response against bacterial pathogens through innovative therapeutic enzymes. The company is currently engaged in pre-clinical research, demonstrating promising results with an enzyme candidate that has achieved 100% protection against lethal Streptococcus pneumoniae infection. With a commitment to collaboration, Pneumotactix is open to exploring new opportunities and is equipped to work internationally. The team invites potential partners to initiate discussions about project proposals and collaborations. Generated from the website